New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
about
Epigenetic control of HIV-1 post integration latency: implications for therapyChallenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsDesigning and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1Manipulation of the host protein acetylation network by human immunodeficiency virus type 1Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusHIV-1 functional cure: will the dream come true?Dynamic models of viral replication and latencyTargeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latencyMulti-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersUsing animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchAre T cells the only HIV-1 reservoir?Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsAchieving HIV-1 Control through RNA-Directed Gene RegulationUnderstanding HIV latency: the road to an HIV cureActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapySynergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb ActivationAn In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionPredicting the outcomes of treatment to eradicate the latent reservoir for HIV-1Latency reversal and viral clearance to cure HIV-1.A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.Function through synthesis-informed designTargeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsMeasuring reversal of HIV-1 latency ex vivo using cells from infected individualsThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.Immunologic strategies for HIV-1 remission and eradication.A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties.Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone coreHIV-1 DNA predicts disease progression and post-treatment virological control.Broadly neutralizing antibodies suppress HIV in the persistent viral reservoirShort chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Translational challenges in targeting latent HIV infection and the CNS reservoir problem.Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.
P2860
Q26781191-EA50E7C5-7379-4C83-97F5-2266F7800004Q26781511-C4CEE926-ADB7-4956-89F4-AFEE898891C4Q26781918-3101C7C8-5284-4B09-9CC7-9B3354D86E84Q26795463-88B33706-1C3B-45F9-9C07-0108D782FD24Q26797870-13C6D068-89BF-427F-B9D7-EA040CF417BFQ26865803-16DC8B02-3A4B-4A7B-923C-E0F4E3EEA5D8Q26866136-47B47040-49B2-4A0D-96D1-60984F1B42D1Q27026631-B9970A23-2343-4CA5-AFDB-67F67ED852E0Q27312050-09EA7551-0766-49DB-899A-64454838A599Q28077662-CA9742F4-C8F9-4CF6-9F96-8C7E1EF6A88BQ28078850-4DA41BBB-2843-4FE4-97A8-1CD1C31FBEF8Q28079455-AB58017C-F214-40FD-A5E3-0AF9E29F186FQ28080090-18235245-C1CF-4A98-B658-C8390B92E990Q28085296-BEAAD62A-1C67-482E-9F0D-363038EC457AQ28544949-5A65E03E-6FF4-47C8-898C-895FBC81ADD3Q28546901-B943FCBA-8BC8-4A41-8430-E24B7D410C61Q28546918-A8CA1EFB-1F77-42A8-9D37-875BC5FBEF58Q28655602-EEFB89A2-A8A9-4D8C-9061-176766B45541Q30248766-D41955DF-45D0-4B91-9C67-C384CD9A00B3Q30385378-82919B15-3ECF-4B1C-B0A8-15DE0729F020Q30904733-F0242A6A-139E-4599-BA28-58FA8DCA3C9BQ33613493-35BD4BB2-2262-497D-9F9F-85676F3AB836Q33627182-4894FB2B-0A12-4D0C-98F1-4DBC100AD36AQ33725916-268C769E-32BB-40C6-8831-43C5DD1311B0Q33817708-447C08E4-5A00-4916-8091-E0886AF51825Q33896523-6D8C8EB5-795D-43DB-953A-1D6059FBAAC9Q33911247-85653E4A-5A63-419A-8F47-B7BC0AC7F574Q34180174-1952C363-2CC4-481D-9C07-0F043DEDA876Q34282542-BE70194C-A78A-43F6-8932-A7933B3E3ED1Q34282624-139C923B-B18F-45D2-B5A3-7D42A6691150Q34350410-253B9FE6-95DF-400F-B0D8-4DC1FAA911DEQ34583552-71B42362-3DD2-4D23-BDAD-D35FAF9378ACQ34656952-39DFC9AA-8D4F-4A84-AE01-60063A0EDD2CQ34869927-38B5DCC3-DA08-4DF0-BE27-056EC464CC11Q35009744-74B8312F-2F35-4F99-8BF3-A18CE389EE5CQ35100672-07D38922-F4BE-4609-BA35-1A0F7F25F7FEQ35100694-AB7BDFDC-E2D3-455E-9908-A996BE500D38Q35168379-151F649C-66AB-4748-8E35-E2573CD50945Q35176166-A5FB68F5-F6C5-4072-9966-53A17AFD86F0Q35252186-78E7CF92-8FB2-4837-946A-E5AFC660742F
P2860
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@en
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@nl
type
label
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@en
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@nl
prefLabel
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@en
New ex vivo approaches disting ...... versing HIV-1 latency in vivo.
@nl
P2093
P2860
P356
P1433
P1476
New ex vivo approaches disting ...... eversing HIV-1 latency in vivo
@en
P2093
C Korin Bullen
Gregory M Laird
Janet D Siliciano
P2860
P2888
P304
P356
10.1038/NM.3489
P407
P577
2014-03-23T00:00:00Z